Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy

Cancer

Volumn 79, Issue 1, 1997, Pages 75-80

  Bonin, Steven R ^a   Hanlon, Alexandra L ^a   Robert Lee, W ^a   Movsas, Benjamin ^a   Al Saleem, T I ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

extracapsular extension; perineural invasion; prostate carcinoma; prostate specific antigen; radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031034394     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3     Document Type: Article

References (26)

1. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Clin Oncol 1995;154:456-9.
2. Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. J Clin Oncol 1996;14:1093-7.
3. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 1995;31:21-4.
4. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995;13:464-9.
5. Pinover WH, Hanlon A, Lee WR, Kaplan EJ, Hanks GE. Prostate carcinoma patients upstaged by imaging and treated with irradiation. Cancer 1996;77:1334-41.
6. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-63.
7. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
8. Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, Movsas B. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher dosed in patients with pretreatment prostate specific antigen ≥ 10 ng/mL. Int J Radiat Oncol Biol Phys In press.
9. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group. Urology 1995;45:616-23.
10. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of RTOG Protocol 85-31) [Abstract 631]. Proc Am Soc Clin Oncol 1995;14:236.
11. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with clinically localized prostate cancer. J Urol 1993;150:110-4.
12. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical Stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993;17:336-41.
13. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. Am J Surg Pathol 1996;20:286-92.
14. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
15. Hanks GE, Schultheiss TE, Hunt M. Clinical experience with 3D radiotherapy treating prostate cancer. Proceedings of International Symposium on 3D Radiation Treatment of Prostate Cancer. St. Louis, MO, April 1993.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Cox DR. Regression methods and life tables (with discussion). J R Stat Soc 1972;34:187-220.
19. Bostwick DG, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155:1361-7.
20. Epstein JI, Carmichael MJ, Pizov G, Walsh PW. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long term followup. J Urol 1993;150:135-41.
21. Eskelinen M, Lipponen P, Syrjanen K. Nucleolar organiser regions (AgNORs) related to histopathological characteristics and survival in prostatic adenocarcinoma. Anticancer Res 1992;12:1635-40.
22. Ravery V, Boccon-Gibod LA, Meulemans A, Dauge-Geffroy MC, Toublanc M. Predictive value of pathological features for progression after radical prostatectomy. Eur Urol 1994;26:197-201.
23. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995;26:223-9.
24. Epstein JI. Pathologic evaluation of prostatic carcinoma: critical information for the oncologist. Oncology 1996; 10:527-34.
25. Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989;142:763-8.
26. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys In press.